OncoMatch/Clinical Trials/NCT06857292
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy
Is NCT06857292 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Telpegfilgrastim for chemotherapy-induced neutropenia.
Treatment: Telpegfilgrastim — This study is a multicenter, single-arm, prospective study. The study population includes children with cancer who require high-intensity chemotherapy. The study aims to evaluate the safety and effectiveness of Telpegfilgrastim in preventing neutropenia in children with cancer (neuroblastoma, sarcoma, lymphoma, etc.) undergoing chemotherapy, while also studying the pharmacokinetic characteristics of Telpegfilgrastim in children with cancer.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: recombinant human G-CSF
Received any rhG-CSF within 3 weeks prior to study participation
Cannot have received: antibody-drug conjugate
Received any antibody coupling drug (ADC) drugs with potential blood toxicity within 3 weeks before participating in the study
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L, PLT ≥ 80×10^9/L, Hb ≥ 75g/L, WBC ≥ 3.0×10^9/L, and not exceeding the upper limit of normal value
Kidney function
serum creatinine (Cr.) ≤ 1.5x ULN
Liver function
Liver function test: total bilirubin (TBIL), ALT, and AST ≤ 2.5x ULN
Normal hematopoietic function of bone marrow (ANC≥1.5×10^9/L, PLT≥80×10^9 /L, Hb≥75g/L, WBC≥3.0×10^9/L, and not exceeding the upper limit of normal value); Liver function test: total bilirubin (TBIL) alanine aminotransferase (ALT.) and aspartate aminotransferase (AST.) were more than 2.5 times the upper limit of normal value; Renal function test: serum creatinine (Cr.) > 1.5 times the upper limit of normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify